ライフサイエンスコーパス: neuropeptide Y

1 avage of a host protein-derived peptide (pro-neuropeptide Y).

2 es such as stromal cell-derived factor-1 and neuropeptide Y.

3 decarboxylase-67 (GAD67), somatostatin, and neuropeptide Y.

4 ell type-specific distribution of endogenous neuropeptide Y.

5 e pool neurons that already express GABA and neuropeptide Y.

6 amage, and compensatory changes in EAAT3 and neuropeptide Y.

7 abundant levels of tyrosine hydroxylase and neuropeptide Y.

8 estrogen receptor-alpha colocalization with neuropeptide Y.

9 so synthesize a range of peptides, including neuropeptide Y.

10 ferent orexigenic molecules: AgRP; GABA; and neuropeptide Y.

11 OM), vasoactive intestinal peptide (VIP), or neuropeptide Y.

12 lar (3V) infusions of the orexigenic peptide neuropeptide Y 3-36 in awake, freely moving rats and det

13 dNPF is an ortholog of the mammalian neuropeptide Y, a highly conserved neuromodulator that s

14 rocessed for immunocytochemistry for SST and neuropeptide Y, a neuropeptide partially coexpressed in

15 In the current study, we found that neuropeptide Y, a protein produced by neurons, affected

16 Neurons coexpressing neuropeptide Y, agouti-related peptide, and GABA (NAG) p

17 Hypothalamic neuropeptide Y, agouti-related peptide, and proopiomelan

18 icted neuronal subsets (proopiomelanocortin, neuropeptide Y/agouti-related peptide, and steroidogenic

19 ng hormone neurons but has limited effect on neuropeptide Y/agouti-related protein and proopiomelanoc

20 ellular mechanism in proopiomelanocortin and neuropeptide Y/agouti-related protein neurons and links

21 ons of the arcuate nucleus, specifically the neuropeptide Y/agouti-related protein neurons and the do

22 ances the activity of agouti-related protein/neuropeptide Y (AgRP/NPY)-expressing neurons but induces

23 approaches we show this plasticity requires neuropeptide Y, an adrenal cotransmitter and the activat

24 f sympathetic nerves and tissue abundance of neuropeptide-Y, an indicator of sympathetic nerve activi

25 (-/-) mice, and other transcripts, including neuropeptide Y and activating transcription factor-3, ar

26 reduced appetite-stimulating neuropeptides, neuropeptide Y and Agouti-related peptide.

27 d by arcuate nucleus neurons that co-express neuropeptide Y and agouti-related protein (NPY/AgRP neur

28 d food intake, body weight, and hypothalamic neuropeptide Y and Agouti-related protein mRNA expressio

29 nduced hepatic FGF21, which caused increased neuropeptide Y and agouti-related protein mRNAs in the h

30 he regulation of social behavior (especially neuropeptide Y and corticotropin-releasing factor) are m

31 disorder are enhanced hippocampal levels of neuropeptide Y and EAAT3 and increased calpain proteolys

32 at co-express agouti-related protein (AgRP), neuropeptide Y and gamma-aminobutyric acid (GABA) are kn

33 control animals and had lower expression of neuropeptide Y and higher expression of proopiomelanocor

34 wn neuropeptides were not detected including neuropeptide Y and neurotensin.

35 In the arcuate nucleus, both Neuropeptide Y and proopiomelanocortin cells expressed t

36 f brainstem and hypothalamic neurons express neuropeptide Y and proopiomelanocortin in the arcuate nu

37 ons of the hypothalamus and colocalizes with neuropeptide Y and proopiomelanocortin neurons in the ar

38 of GABAergic GAD67+ interneurons expressing neuropeptide Y and somatostatin are reduced in the hippo

39 2.2 is not required for the specification of neuropeptide Y and vasoactive intestinal polypeptide, in

40 coneogenic enzymes and elevated hypothalamic neuropeptide-Y and agouti-related protein mRNA levels.

41 n analogue of the C-terminal pentapeptide of neuropeptide Y, and a neuropeptide FF analogue) were sub

42 othalamic neuropeptides proopiomelanocortin, neuropeptide Y, and agouti-related peptide in T1D mice.

43 Ivy cells express nitric oxide synthase, neuropeptide Y, and high levels of GABA(A) receptor alph

44 -regulating proteins agouti-related peptide, neuropeptide Y, and uncoupling protein 2 in the hypothal

45 hich express the orexigenic neuronal marker, Neuropeptide-Y, and respond to fasting and leptin-induce

46 Injections of Aplysia neuropeptide Y (apNPY) reduced food intake and slowed do

47 Agouti-related peptide (AGRP) and Neuropeptide Y are potent orexigens and are coexpressed

48 ress characteristic combinations of GABA and neuropeptide Y as cotransmitters and Lim1,2 and Nurr1 tr

49 he modulation of neurotransmitter release by neuropeptide Y, baclofen, and adenosine as revealed by [

50 the insulin promotor (Ins2) were stained for neuropeptide Y before, during, and after virally induced

51 s that synthesize agouti-related peptide and neuropeptide Y but inhibited anorexigenic neurons that s

52 e BBB-impermeable neuropeptides dalargin and neuropeptide Y chemically conjugated with FC5-Fc fusion

53 .93]) after stressful training; lower plasma neuropeptide Y concentration after stressful training (d

54 ures were heart rate, breathing rate, plasma neuropeptide Y concentration, score on the Response to S

55 Neuropeptide Y-containing interneurons in the dentate hi

56 eurons that are defined by the expression of neuropeptide Y::Cre (NPY::Cre) act to gate mechanical it

57 Neuropeptide Y detection was performed.

58 the mammalian target of rapamycin pathway in neuropeptide-Y-ergic neurons of the arcuate nucleus, and

59 A significant reduction of calbindin-, NPY (neuropeptide Y)-expressing, and cholinergic interneurons

60 ic inhibitory circuit involving a variety of neuropeptide Y-expressing interneurons.

61 endrites, whereas nitric oxide synthase- and neuropeptide Y-expressing ivy cells provided synaptic an

62 In addition, we found neuropeptide Y expression almost exclusively in those GI

63 Surprisingly, hypothalamic neuropeptide Y expression was completely suppressed, sug

64 nders to two model peptides, angiotensin and neuropeptide Y, following screening by solution phage pa

65 g mice showed increased levels of C-terminal neuropeptide Y fragments and increased neurogenesis.

66 europeptide F (NPF), a homolog of vertebrate neuropeptide Y, functions in feeding and coordination of

67 single nucleotide polymorphism (SNP) in the neuropeptide Y gene has been associated with elevated se

68 Both serotonin (5-HT) and neuropeptide Y have been shown to affect a variety of ma

69 essing Drosophila neuropeptide F (dNPF), the neuropeptide Y homolog, strongly correlates with food-od

70 leasing short neuropeptide F, the Drosophila neuropeptide Y homolog.

71 used immunohistochemistry for calretinin and neuropeptide Y in 24 age- and gender-matched patients wi

72 nthesize gamma-amino-butyric acid (GABA) and neuropeptide Y in adult mice leads to starvation within

73 d release of the orexigenic neurotransmitter neuropeptide Y in response to glucose.

74 ons expressing parvalbumin, somatostatin and neuropeptide Y in the dentate gyrus, reduced aberrant ne

75 pro-opiomelanocortin/agouti-related peptide/neuropeptide Y in the hypothalamus of the rats.

76 ar responsiveness and vascular reactivity to neuropeptide Y in the offspring.

77 rvating (calretinin(+), somatostatin(+), and neuropeptide Y(+)) interneurons.

78 TH-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in MPH-exposed rats.

79 Numbers of neuropeptide Y-IR neurons were not affected.

80 osal plexus and was expressed exclusively by neuropeptide Y-IR neurons.

81 Neuropeptide Y is a key peptide affecting adiposity and

82 neuropeptides such as ghrelin, orexin A and neuropeptide Y is also discussed.

83 Multiple peptide systems, including neuropeptide Y, leptin, ghrelin, and others, are involve

84 P, corticotropin releasing factor (CRF), and neuropeptide Y levels in adult male Long-Evans rats defe

85 ng neuropeptide F receptor 1, a receptor for neuropeptide Y-like neuropeptide F.

86 n and attraction is thought to depend on the neuropeptide Y-like receptor NPR-1, because solitary and

87 ting cells and identified neurons expressing neuropeptide Y-like short neuropeptide F (sNPF).

88 -expressing interneurons and initiation of a neuropeptide-y-like signaling axis that promotes elevate

89 cystokinin/CB(1) cannabinoid receptor(+) and neuropeptide Y(+) local-circuit interneurons upon SAVA m

90 f both Lifeact-GFP and the SG marker protein neuropeptide Y-mCherry reveals that SGs actively translo

91 neuropeptide F, the invertebrate homolog of neuropeptide Y, modulate aggression.

92 tissue weight, fecal output, arcuate nucleus neuropeptide Y mRNA expression, plasma corticosterone, a

93 ng hormone but surprisingly has no effect on neuropeptide Y mRNA, a neuropeptide previously shown to

94 Neuropeptide Y neurons have been shown to be particularl

95 s, stimulation of the agouti-related protein/neuropeptide Y neurons, and activation of the hypothalam

96 lly significant difference in the density of neuropeptide Y+ neurons between subjects with autism and

97 n, corticotropin releasing hormone, galanin, neuropeptide Y, neurotensin, preproenkephalin and tachyk

98 in, dynorphin) and brain antistress systems (neuropeptide Y, nociceptin [orphanin FQ]) in drug depend

99 r, metabotropic glutamate receptors-2 mGlu2, neuropeptide-Y NPY, and mineralocorticoid receptors MR).

100 d identify the vasoconstrictive mechanism as Neuropeptide Y (NPY) acting on Y1 receptors.

101 e truncated cleaved form of neurotransmitter neuropeptide Y (NPY) actively promotes a breach of BM va

102 Neuropeptide Y (NPY) administration into the basolateral

103 Bioconjugates containing the neuropeptide Y (NPY) analogue [F(7),P(34)]-NPY as target

104 In lean mice, the adipokine leptin inhibits neuropeptide Y (NPY) and agouti-related peptide (AgRP) n

105 bits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) v

106 Hypothalamic neurons that express neuropeptide Y (NPY) and agouti-related protein (AgRP) a

107 Neuropeptide Y (NPY) and Agouti-related protein (AgRP),

108 the expression of orexigenic neuropeptides [neuropeptide Y (NPY) and agouti-related protein (AgRP)]

109 with changes in orexigenic peptides such as neuropeptide Y (NPY) and anorexigenic peptides such as a

110 s that regulate stress and reward, including neuropeptide Y (NPY) and corticotropin-releasing factor

111 s, including somatostatin (SST), tachykinin, neuropeptide Y (NPY) and cortistatin, in a pattern remin

112 was developed for the sensitive detection of neuropeptide Y (NPY) and employed in the analysis of NPY

113 LIF also regulates expression of both neuropeptide Y (NPY) and galanin following peripheral ne

114 c), containing pro-opoiomelanocortin (POMC), neuropeptide Y (NPY) and growth hormone releasing hormon

115 Neuropeptide Y (NPY) and its receptors (especially Y1, Y

116 up-regulating specific target genes, such as neuropeptide Y (NPY) and its Y1 and Y5 receptors (Y5Rs).

117 and modulation of neurological signals, with Neuropeptide Y (NPY) and Orexin A (OXA) offering diagnos

118 Neuropeptide Y (NPY) and pancreatic polypeptide (PP) con

119 ion of corticotropin releasing factor (CRF), neuropeptide Y (NPY) and proopiomelanocortin (POMC) in h

120 the lateral hypothalamus (LH) together with neuropeptide Y (NPY) and proopiomelanocortin (POMC) neur

121 the total number of interneurons expressing neuropeptide Y (NPY) and vasoactive intestinal polypepti

122 Other peptides such as neuropeptide Y (NPY) are synthesized throughout the brai

123 sh, and here we report the identification of neuropeptide Y (NPY) as both necessary for normal daytim

124 in a structural model of the peptide hormone neuropeptide Y (NPY) bound to its human G-protein-couple

125 in the basolateral amygdaloid complex (BLA), neuropeptide Y (NPY) buffers against protracted anxiety

126 e ontogeny of proopiomelanocortin (POMC) and neuropeptide Y (NPY) cell populations, which exert oppos

127 pocretin cells respond to dynorphin, arcuate neuropeptide Y (NPY) cells respond to hypocretin], diffe

128 stimulatory connections onto the neighboring neuropeptide Y (NPY) cells.

129 strongly implicated hindbrain catecholamine/neuropeptide Y (NPY) coexpressing neurons as key mediato

130 ression of agouti-related protein (Agrp) and neuropeptide Y (Npy) coincide with the cyclic changes in

131 c (tg) mice affected primarily the levels of neuropeptide Y (NPY) compared with other neuropeptides.

132 subpopulation of CA1 interneurons expressing neuropeptide Y (NPY) contributes prominently to this dyn

133 Neuropeptide Y (NPY) counters stress and is involved in

134 we show that the claims of Zhou et al. that neuropeptide Y (NPY) diplotype-predicted expression is c

135 The DMH contains neurons expressing Neuropeptide Y (NPY) during specific physiological condi

136 s glucocorticoids have pronounced effects on neuropeptide Y (NPY) expression and as NPY neurons proje

137 gered molecular plasticity including ectopic neuropeptide Y (NPY) expression in granule cells, but wi

138 element binding) binding protein (CBP), and neuropeptide Y (NPY) expression in the amygdaloid brain

139 binding protein (CREB) resulted in decreased neuropeptide Y (NPY) expression in the central amygdala

140 icular and dorsomedial nuclei, and increased neuropeptide Y (NPY) expression in the hypothalamus.

141 Because neuropeptide Y (NPY) expression is strongly induced in D

142 pression of vGLUT1 but not vGAT, and reduced Neuropeptide Y (NPY) expression.

143 genesis with emphasis on the distribution of neuropeptide Y (NPY) expression.

144 nes and their cognate receptors belonging to neuropeptide Y (NPY) family mediate diverse biological f

145 The neuropeptide Y (NPY) family of peptides and receptors re

146 ucagon-like peptide-1 (GLP-1), glucagon, and neuropeptide Y (NPY) from circumvallate papillae of Tas1

147 Neuropeptide Y (NPY) gene expression in the hippocampal

148 Recent studies indicate that neuropeptide Y (NPY) has a major role in the regulation

149 anxiety and other psychiatric disorders and neuropeptide Y (NPY) has emerged as a key component of a

150 Neuropeptide Y (NPY) has robust anxiolytic properties an

151 SIGNIFICANCE STATEMENT: Neuropeptide Y (NPY) has robust anxiolytic properties, a

152 While recent animal studies of neuropeptide Y (NPY) have suggested a facilitator role f

153 nd that appetite-regulating systems, such as neuropeptide Y (NPY) in the arcuate nucleus (ARH) and or

154 Previous studies have suggested that neuropeptide Y (NPY) in the dorsomedial hypothalamus (DM

155 The expression of the orexigenic neuropeptide Y (NPY) in the hypothalamus to the low lept

156 However, the specific role of neuropeptide Y (NPY) in this process has not been system

157 Neuropeptide Y (NPY) interacts with the Y(1) receptor, N

158 ic inputs to the two populations of striatal neuropeptide Y (NPY) interneurons, plateau low threshold

159 Neuropeptide Y (NPY) is a 36-amino-acid peptide transmit

160 Neuropeptide Y (NPY) is a hypothalamic neuropeptide that

161 Neuropeptide Y (NPY) is a peptide known for its anti-anx

162 Neuropeptide Y (NPY) is a putative endogenous anxiolytic

163 Neuropeptide Y (NPY) is a well-established orexigenic pe

164 Neuropeptide Y (NPY) is an important modulatory neuropep

165 Neuropeptide Y (NPY) is an important peptide regulating

166 Neuropeptide Y (NPY) is anxiolytic and its release is in

167 Neuropeptide Y (NPY) is induced in peripheral tissues su

168 Neuropeptide Y (NPY) is one of the major neuropeptides p

169 Neuropeptide Y (NPY) is one of the most abundant protein

170 Neuropeptide Y (NPY) is one of the most widespread neuro

171 cord following inflammation or nerve injury, neuropeptide Y (NPY) is poised to regulate the transmiss

172 ported that the sympathetic neurotransmitter neuropeptide Y (NPY) is potently angiogenic, primarily t

173 Neuropeptide Y (NPY) is produced in the intergeniculate

174 evious observations that fluorescent-labeled neuropeptide Y (NPY) is usually released within 200 ms a

175 Neuropeptide Y (NPY) is widely expressed in the central

176 ICV TTR decreased neuropeptide Y (NPY) levels in the DMH and the paraventr

177 understand whether genetic variation at the Neuropeptide Y (NPY) locus governs secretion and stress

178 Neuropeptide Y (NPY) mediates stress-induced obesity in

179 Acute administration of neuropeptide Y (NPY) modulates alcohol intake in genetic

180 cordings were made from GFP (Renilla)-tagged neuropeptide Y (NPY) neurons from the arcuate nucleus of

181 Neuropeptide Y (NPY) neurons in both the arcuate nucleus

182 nhibitory effect of Dyn-A on arcuate nucleus neuropeptide Y (NPY) neurons mediated by both 1 and (kap

183 In contrast, kisspeptin inhibits orexigenic neuropeptide Y (NPY) neurons through an indirect mechani

184 The DMH contains orexigenic neuropeptide Y (NPY) neurons, but the role of these neur

185 ts of intracerebroventricular application of Neuropeptide Y (NPY) on licking microstructure for sucro

186 he purpose of this study was to characterize neuropeptide Y (NPY) overflow and metabolism from isolat

187 Recent studies suggest that human neuropeptide Y (NPY) plays a prominent role in managemen

188 nt protein is expressed under control of the neuropeptide Y (NPY) promoter and striatal NPY-expressin

189 a green fluorescent protein (GFP) under the neuropeptide Y (NPY) promoter.

190 e neuropeptide F receptor NPFR1, a mammalian neuropeptide Y (NPY) receptor homolog, centrally regulat

191 he autonomic nervous system and hypothalamic neuropeptide Y (NPY) release during fasting regulates he

192 Neuropeptide Y (NPY) signaling in the CNS was modulated

193 Neuropeptide Y (NPY) stimulates feeding and weight gain,

194 In the current study, we found that neuropeptide Y (NPY) suppressed monocyte recruitment to

195 on requires simultaneous withdrawal of tonic neuropeptide Y (NPY) sympathoinhibition.

196 It has been speculated this alters neuropeptide Y (NPY) synthesis, trafficking, or secretio

197 Functional genetic variation of neuropeptide Y (NPY) was recently identified as a source

198 fibers coexpress the inhibitory transmitter neuropeptide Y (NPY) with glutamate.

199 udied the role of alpha(2)-adrenoceptors and neuropeptide Y (NPY) Y(1) receptors in mediating vasocon

200 r-NH(2)](2), 1, to be a moderately selective neuropeptide Y (NPY) Y(4) receptor agonist.

201 We applied this BiFC system to study example neuropeptide Y (NPY) Y1 receptor dimers.

202 d the role of alpha-adrenergic receptor- and neuropeptide Y (NPY) Y1 receptor-mediated vasoconstricti

203 Activation of neuropeptide Y (NPY) Y1 receptors (Y1r) in the rat basol

204 Normal breast tissue mainly expresses the neuropeptide Y (NPY) Y2 receptor whereas primary human b

205 ations of GABAergic interneurones expressing neuropeptide Y (NPY)(+), parvalbumin (PV)(+) and tyrosin

206 neurons [gamma-aminobutyric acid (GABA)(+), neuropeptide Y (NPY)(+), proopiomelanocortin (POMC)(+),

207 Neuropeptide Y (NPY), a 36 aa peptide, regulates stress

208 Neuropeptide Y (NPY), a brain neuromodulator that has be

209 Double labeling with neuropeptide Y (NPY), a marker for vasomotor neurons, re

210 study, we identified increased expression of neuropeptide Y (NPY), a pleiotropic growth factor which

211 have studied the subcellular distribution of neuropeptide Y (NPY), a prototypical and broadly express

212 Neuropeptide Y (NPY), a stress modulatory transmitter, i

213 Our previous studies have identified neuropeptide Y (NPY), a sympathetic neurotransmitter exp

214 In birds, CART inhibits food intake, whereas neuropeptide Y (NPY), a well-known orexigenic peptide, s

215 ry indicate that cortical astrocytes contain neuropeptide Y (NPY), a widespread neuronal transmitter.

216 from chemotherapy-induced cell death, while neuropeptide Y (NPY), acting via its Y2 receptor (Y2R),

217 c neuron markers proopiomelanocortin (POMC), neuropeptide Y (NPY), agouti-related peptide (AGRP), som

218 ment, hypothalamic mRNA expression levels of neuropeptide Y (NPY), agouti-related protein (AGRP), pro

219 We studied the actions of neuropeptide Y (NPY), an abundant neocortical neuropepti

220 se changes are regulated postsynaptically by neuropeptide Y (NPY), an adrenal cotransmitter.

221 ted whether VPA influences the expression of neuropeptide Y (NPY), an endogenous anticonvulsant.

222 creased mRNA levels of hypothalamic GHS-R1a, neuropeptide Y (NPY), and agouti-related protein (AgRP),

223 (CB), parvalbumin (PV), calretinin (CR) and neuropeptide Y (NPY), and somatostatin (SOM) and glial f

224 augments the SCN clock-resetting effects of neuropeptide Y (NPY), another neurochemical correlate of

225 ctor 3 (ATF3), the neuropeptides galanin and neuropeptide Y (NPY), brain-derived neurotrophic factor

226 scription level: monoamine oxidase A (MAOA), neuropeptide Y (NPY), endothelial nitric oxide synthase

227 -melanocyte-stimulating hormone (alpha-MSH), neuropeptide Y (NPY), glutamate, and GABA from first-ord

228 ), galanin, gastrin-releasing peptide (GRP), neuropeptide Y (NPY), nitric oxide synthase (NOS), serot

229 ed by either gamma-aminobutyric acid (GABA), neuropeptide Y (NPY), or beta-endorphin receptor blockad

230 Immunohistochemistry for somatostatin (SOM), neuropeptide Y (NPY), parvalbumin (PV), cholecystokinin

231 vels of genes that regulate appetite, namely neuropeptide Y (NPY), pro-opiomelanocortin (POMC) and th

232 he well-characterized neuropeptides, such as neuropeptide Y (NPY), proopiomelanocortin (POMC), orexin

233 ent with PEDF + DHA induced transcription of neuropeptide y (npy), small proline-rich protein 1a (spr

234 GFP) in a subset of neurons that colocalized neuropeptide Y (NPY), somatostatin (SST), and GABA for w

235 xp4 expression induces ectopic expression of neuropeptide Y (Npy), which has been reported to be pres

236 effects were due to disrupted signalling of neuropeptide Y (NPY), which is known to mediate non-phot

237 ar interneurons of the dentate gyrus express neuropeptide Y (NPY), which modulates granule cell activ

238 One relevant target is neuropeptide Y (NPY), which regulates both stress and fo

239 l transduction pathway modulating release of neuropeptide Y (NPY), which stimulates OE stem cell acti

240 cell activation and promotes the activity of neuropeptide Y (NPY)- and agouti-related peptide (AgRP)-

241 nterneurons express col19a1 mRNA; subsets of neuropeptide Y (NPY)-, somatostatin (Som)-, and calbindi

242 e investigated the properties of neostriatal neuropeptide Y (NPY)-expressing interneurons in transgen

243 1 (GAD1) in either cholecystokinin (CCK)- or neuropeptide Y (NPY)-expressing interneurons.

244 on, appeared to be precipitated by a loss of neuropeptide Y (NPY)-mediated local circuit inhibition a

245 ood attraction to aversion is regulated by a neuropeptide Y (NPY)-related brain signaling peptide.

246 expressing agouti-related peptide (AgRP) and neuropeptide Y (Npy).

247 ropeptides agouti-related protein (AgRP) and neuropeptide Y (NPY).

248 e-like ethanol drinking to study the role of neuropeptide Y (NPY).

249 r producing the neuropeptides enkephalin and neuropeptide Y (NPY).

250 III are GABAergic, and some of these express neuropeptide Y (NPY).

251 rsors and express neuronal proteins, such as neuropeptide Y (NPY).

252 n enzyme that truncates the neurotransmitter neuropeptide Y (NPY).

253 F co-receptors GFRalpha1 and RET, as well as neuropeptide Y (NPY).

254 release of the anticonvulsant neuropeptide, neuropeptide Y (NPY).

255 nal white adipose tissue that is mediated by neuropeptide Y (NPY).

256 e stimulating hormone (alpha-MSH) as well as neuropeptide Y (NPY).

257 ented for the expression of a third peptide, neuropeptide Y (NPY).

258 increase in haemoglobin, catecholamines and neuropeptide Y (NPY).

259 asting discharge rates of fluorescent-tagged neuropeptide-Y (NPY) (within 200 ms) and tissue plasmino

260 that express pro-opiomelanocortin (POMC) or neuropeptide-Y (NPY) and agouti-related protein (AgRP).

261 escence microscopy of lumen-targeted probes (neuropeptide Y [NPY]-pH-insensitive yellow fluorescent p

262 ridization to localize appetite-stimulating (neuropeptide Y, NPY; agouti-related protein, AGRP) and a

263 cal activity: the N-terminal region of human neuropeptide Y (NPY1-9, Tyr(1)-Pro(2)-Ser(3)-Lys(4)-Pro(

264 tostatin, vasoactive intestinal polypeptide, neuropeptide Y, or cholecystokinin (antigens commonly co

265 Vascular reactivity to neuropeptide Y (P<0.05) and electrical field stimulation

266 Furthermore, loss of calbindin, neuropeptide Y, parvalbumin, and GAD65-positive interneu

267 r morphology and expression of somatostatin, neuropeptide Y, parvalbumin, or calretinin, we infer tha

268 The neuropeptide Y pathway acts together with SRB-13 to anta

269 The possible involvement of neuropeptide Y pathways during 2DG-induced expression of

270 creatic polypeptide (PPY) are members of the neuropeptide Y peptide family.

271 e submucosal plexus, DOReGFP was detected in neuropeptide Y-positive secretomotor and vasodilator neu

272 Loss of neuropeptide Y prevents a fasting-induced increase in ep

273 pressing green fluorescent protein under the neuropeptide Y promoter, we find that, across all layers

274 tance P, calcitonin gene-related peptide, or neuropeptide Y protein expression in DRGs and spinal cor

275 Lower mRNA levels of neuropeptide Y receptor 1 (NPY1R) and NPY5R but not NPY

276 boratory-derived, mutation controlled by the neuropeptide Y receptor homolog npr-1 can affect dauer l

277 The neuropeptide Y receptor homolog, NPR-1, and an inhibitor

278 multiple signaling molecules, including the neuropeptide Y receptor NPR-1 and the calcineurin subuni

279 The neuropeptide Y receptor signaling pathway has been impli

280 on and this effect was blocked by a specific neuropeptide Y receptor Y1 (NPY1R) antagonist.

281 ion, although this was blocked by a specific neuropeptide Y receptor Y1 receptor antagonist, suggesti

282 ne, which encodes a homolog of the mammalian neuropeptide Y receptor.

283 coupled receptor (GPCR) related to mammalian neuropeptide Y receptors, functions to suppress innate i

284 uantification of neuronal glucocorticoid and neuropeptide Y receptors.

285 Y1 receptor (Y1R) and Y5 receptor (Y5R) for neuropeptide Y share similar actions in the regulation o

286 ive deficits, as well as endocannabinoid and neuropeptide Y system alterations and altered circadian

287 The neuropeptide Y system consists of several neuropeptides

288 er was monitored by observing DCV-associated neuropeptide Y tagged with a fluorescent protein.

289 receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field o

290 d tumor necrosis factor, whereas addition of neuropeptide Y to wild-type macrophages attenuates the r

291 s-associated increase of immunoreactivity of neuropeptide Y, tyrosine hydroxylase, and somatostatin.

292 In contrast, interneurons containing neuropeptide Y, vasoactive intestinal peptide, or the 5-

293 Neuropeptide Y was elevated in the caudate-putamen.

294 hypothalamic expression of the orexic gene, neuropeptide Y, was lower and expression of the anorexic

295 (AgRP) neurons (which also release AgRP and neuropeptide Y), we generated mice with an AgRP neuron-s

296 (AgRP) neurons (which also release AgRP and neuropeptide Y), we generated mice with an AgRP neuron-s

297 ropeptide F (sNPF), an ortholog of mammalian neuropeptide Y, which we show here is a direct target of

298 The results suggest that neuropeptide Y Y1R differentially expressed in the limbi

299 The role of neuropeptide Y Y2 receptor (Y2R) in human diseases such

300 ereomeric mixture) is a potent and selective neuropeptide Y Y4 receptor agonist.